Stay updated on Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Sign up to get notified when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.

Latest updates to the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page
- Check4 days agoChange DetectedThe record’s latest submission and posting dates were updated from July 2026 to November 2026, alongside a minor ClinicalTrials.gov site revision update.SummaryDifference0.1%

- Check11 days agoChange DetectedThe study record for a Phase 3 comparison of selumetinib alone versus selumetinib with vinblastine is displayed, including treatment arms, eligibility criteria, outcomes, and study locations.SummaryDifference100%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision number also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now returns a 403 Forbidden error, replacing the study record content. The detailed study information (title, conditions, locations, eligibility, and plans) has been removed, leaving only generic site chrome and footer text.SummaryDifference21%

- Check67 days agoChange DetectedThe page revision tag was updated from v3.6.6 to v3.7.0. This indicates a new version of the page used for internal tracking, with no explicit changes to the study content evident from the provided data.SummaryDifference0.0%

Stay in the know with updates to Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.